Vijay Chiruvolu
Chief Tech/Sci/R&D Officer chez TURNSTONE BIOLOGICS CORP.
Profil
Vijay Chiruvolu is currently the Chief Technology Officer at Turnstone Biologics Corp.
Prior to this, he was the Chief Technical Officer at Instil Bio, Inc. from 2020 to 2022.
He also held the position of Senior Vice President-Process Development at Kite Pharma, Inc. Dr. Chiruvolu holds an MBA from The Pennsylvania State University and a doctorate from The University of Nebraska-Lincoln.
Postes actifs de Vijay Chiruvolu
Sociétés | Poste | Début |
---|---|---|
TURNSTONE BIOLOGICS CORP. | Chief Tech/Sci/R&D Officer | 01/03/2023 |
Anciens postes connus de Vijay Chiruvolu
Sociétés | Poste | Fin |
---|---|---|
INSTIL BIO, INC. | Chief Tech/Sci/R&D Officer | 02/09/2022 |
KITE PHARMA INC | Corporate Officer/Principal | - |
Formation de Vijay Chiruvolu
The Pennsylvania State University | Masters Business Admin |
The University of Nebraska-Lincoln | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
TURNSTONE BIOLOGICS CORP. | Health Technology |
INSTIL BIO, INC. | Health Technology |
Entreprise privées | 1 |
---|---|
Kite Pharma, Inc.
Kite Pharma, Inc. BiotechnologyHealth Technology Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on 2009 and is headquartered in Santa Monica, CA. | Health Technology |